Table 2

Erlotinib pharmacokinetic and pharmacodynamic effects

CasePathologic responsePretreatment cyclin D1Posttreatment cyclin D1Peak plasma erlotinib concentration (μmol/L)Tumor tissue erlotinib concentration (μmol/L)
1No2+2+6.50.3
2No2+2+3.91.7
3Yes3+1+9.74.1
4Yes2+1+3.04.8
Median concentration5.22.9